



Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)

Sai, Satoshi ; Toyoda, Masanori ; Tobimatsu, Kazutoshi ; Satake, Hironaga ; Yasui, Hisateru ; Kimbara, Shiro ; Koyama, Taiji ;...

(Citation)

Cancer Chemotherapy and Pharmacology, 87(1):65-71

(Issue Date)

2021-01

(Resource Type)

journal article

(Version)

Accepted Manuscript

(Rights)

© Springer-Verlag GmbH Germany, part of Springer Nature 2020. This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature's AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of...

(URL)

<https://hdl.handle.net/20.500.14094/90007832>



Original Article

Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)

Satoshi Sai¹, Masanori Toyoda¹, Kazutoshi Tobimatsu², Hironaga Satake³, Hisateru Yasui³,
Shiro Kimbara¹, Taiji Koyama¹, Yoshimi Fujishima¹, Yoshinori Imamura¹, Yohei Funakoshi¹,
Naomi Kiyota^{1,4}, Hirochika Toyama⁵, Yuzo Kodama² and Hironobu Minami^{1,4}

¹Department of Medical Oncology/Hematology, Kobe University Hospital and Graduate School
of Medicine, Kobe, Japan;

²Department of Gastroenterology, Kobe University Hospital and Graduate School of Medicine,
Kobe, Japan;

³Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center
General Hospital, Kobe, Japan;

⁴Cancer Center, Kobe University Hospital, Kobe, Japan;

⁵Department of Hepato-Biliary-Pancreatic Surgery, Kobe University Hospital and Graduate
School of Medicine, Kobe, Japan

1 **Corresponding author:**

2 Dr. Masanori Toyoda, Department of Medical Oncology/Hematology, Kobe University

3 Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo, 650-0017,

4 Japan.

5 Tel: +81-78-382-5825, Fax: +81-78-382-5821, Email: kobetoyo@med.kobe-u.ac.jp

6

7

8

9

10

11

12

13

14

Abstract

Purpose: We conducted a phase 1 study to determine the maximum tolerated dose and the recommended dose of gemcitabine/nab-paclitaxel/S-1 combination chemotherapy in patients with unresectable pancreatic cancer.

Methods: We enrolled patients aged 20 years or older with unresectable pancreatic cancer and who had not been treated with chemotherapy or radiation therapy. Gemcitabine and nab-paclitaxel were administered on days 1 and 8, and S-1 was administered orally twice daily for 2 weeks, repeated every 3 weeks. The starting dose was level 0 (gemcitabine 700 mg/m², nab-paclitaxel 90 mg/m², S-1 60/80/100 mg/day [$<1.25 \text{ m}^2/1.25\text{-}1.50 \text{ m}^2/>1.5 \text{ m}^2$]). Dose-limiting toxicities were determined during the first course, and a classical 3 + 3 dose finding design was planned.

Results: From March 2018 to October 2019, 20 patients were enrolled. At dose level 0, three of six patients experienced dose-limiting toxicities; one grade 3 skin rash on day 8, and two grade 3 or 4 neutropenia on day 8. At dose level -1 (gemcitabine 600 mg/m², nab-paclitaxel 90 mg/m², and S-1 50/70/80 mg/day), two of twelve patients experienced dose-limiting toxicities, all of which were grade 3 neutropenia on day 8. The most frequently observed toxicity during 8

courses was neutropenia. Other treatment-related adverse events were mild. Eleven out of 19 (58%) patients achieved partial response.

Conclusion: We defined the maximum tolerated dose and the recommended dose for combination therapy with gemcitabine/nab-paclitaxel/S-1 as dose level –1. Considering the observed response rate, further studies are warranted in order to determine the efficacy of this regimen. (UMIN-CTR 000030007)

Keywords: unresectable pancreatic cancer, gemcitabine, nab-paclitaxel, S-1, phase 1

1. Introduction

The prognosis of patients with pancreatic cancer is one of the worst among all malignancies, with an estimated 5-year survival rate of less than 5% [1]. Many cases are diagnosed with locally advanced or distant metastatic disease [2], and the number of deaths due to pancreatic cancer has increased for both men and women over the past decade [3]. One of the reasons for the high mortality rate of pancreatic cancer is that there are no effective chemotherapies to treat the disease. To improve the prognosis of pancreatic cancer, the development of a highly active chemotherapy regimen is necessary.

The standard chemotherapies for unresectable pancreatic cancer are gemcitabine plus nab-paclitaxel combination therapy or FOLFIRINOX therapy. Gemcitabine plus nab-paclitaxel is superior to gemcitabine alone (median overall survival 8.5 months vs 6.7 months, hazard ratio (HR) 0.72) [4]; FOLFIRINOX is also superior to gemcitabine (median overall survival 11.1 months vs 6.8 months, HR 0.57) [5]. Additionally, S-1 (an oral fluoropyrimidine prodrug) is non-inferior to gemcitabine (median overall survival 9.7 months vs 8.8 months, HR 0.96) [6]. Based on these studies, gemcitabine, nab-paclitaxel, 5-fluorouracil, irinotecan, oxaliplatin, and S-1 can be considered key-drugs, and combinations of these drugs are usually used for unresectable pancreatic cancer. Although FOLFIRINOX has a promising HR, its efficacy is

1 limited by the high rate of febrile neutropenia it induces, and the regimen is not considered
2 tolerable in the Japanese population [7, 8]. Therefore, it is usually used as a modified regimen
3 with dose reduction, but superiority of modified FOLFIRINOX to gemcitabine has not been
4 demonstrated in randomized studies. On the other hand, the combination of gemcitabine plus
5 nab-paclitaxel also causes cumulative peripheral neuropathy, leading to treatment interruption
6 or dose reduction [4, 9].

7 Given the paucity of chemotherapeutic options for unresectable pancreatic cancer,
8 there is a clear need to develop a safer and more efficacious new regimen. Previous phase 2
9 trials showed the effectiveness of nab-paclitaxel plus S-1 combination therapy for advanced
10 pancreatic cancer [10, 11]. On the other hand, the FUGA-BT randomized phase 3 trial showed
11 that S-1 combined with gemcitabine was non-inferior to the combination of gemcitabine plus
12 cisplatin in patients with biliary tract cancer [12]. We hypothesized that combining S-1 with
13 gemcitabine plus nab-paclitaxel therapy would have an additive effect on efficacy. We therefore
14 conducted the current phase 1 study to determine the maximum tolerated dose (MTD) and the
15 recommended dose (RD) of the gemcitabine/nab-paclitaxel/S-1 triplet combination
16 chemotherapy in patients with unresectable pancreatic cancer (GeNeS1S).

2. Material and Methods

2.1 Study design

This study was a prospective, multi-center, phase 1 study with a 3 + 3 dose escalation design. The study protocol was approved by the institutional review board of each institution, and written informed consent was obtained from all participants. This study was conducted in accordance with the declaration of Helsinki, the principles of Good Clinical Practice and all applicable regulations. This clinical study was registered in the University hospital Medical Information Network-Clinical Trial Registry (UMIN-CTR), identification number 000030007.

2.2 Eligibility criteria

We recruited patients with unresectable (locally advanced or metastatic) pancreatic cancer. Eligibility criteria were as follows; a histologically or cytologically confirmed diagnosis of pancreatic cancer, aged 20 years or older at registration, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, one or more measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, no previous treatment (radiotherapy, chemotherapy and immunotherapy) for advanced disease, adequate bone marrow

function (neutrophil count $\geq 1500/\text{mm}^3$, hemoglobin ≥ 9.0 g/dL, platelet count $\geq 100,000/\text{mm}^3$), liver function (total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the ULN), renal function (creatinine clearance ≥ 60 ml/min), no serious complications, adequate oral intake, and grade 1 or less peripheral neuropathy. Previous neoadjuvant or adjuvant chemotherapy was allowed if the treatment had ended more than 6 months before recurrence, and biliary drainage (percutaneous, endoscopic or laparotomy) was also allowed. Exclusion criteria were as follows; interstitial pneumonitis or pulmonary fibrosis, uncontrollable diabetes, angina or myocardial infarction within 3 months, severe infection or suspected severe infection with fever, pregnant women, breastfeeding and cases in which women were attempting to become pregnant, severe drug allergies, psychosis or psychiatric symptoms that were considered to pose difficulties during study participation, moderate or higher ascites or pleural effusion, and watery diarrhea that was difficult to control.

2.3 Treatment

The starting dose (dose level 0) was gemcitabine $700 \text{ mg}/\text{m}^2$ and nab-paclitaxel $90 \text{ mg}/\text{m}^2$ on days 1 and 8 combined with S-1 $60/80/100 \text{ mg}/\text{day}$ ($<1.25 \text{ m}^2/1.25\text{-}1.50 \text{ m}^2/>1.5 \text{ m}^2$) orally

twice daily for 2 weeks, repeated every 3 weeks. The treatment period for this study was 24 weeks (8 courses). For the administration on day 1, the criteria to start each course were: neutrophil count $\geq 1500/\text{mm}^3$, hemoglobin ≥ 8.0 g/dl, platelet count $\geq 100,000/\text{mm}^3$, total bilirubin ≤ 1.5 times the ULN, AST and ALT ≤ 3 times the ULN, creatinine clearance ≥ 50 ml/min, non-hematological toxicity related to treatment drug $\leq$ grade 2, and no fever suspected of infection. Similarly, the administration criteria of day 8 were as follows; neutrophil count $\geq 1000/\text{mm}^3$, hemoglobin ≥ 8.0 g/dl, platelet count $\geq 70,000/\text{mm}^3$, total bilirubin ≤ 1.5 times the ULN (≤ 3.0 times the ULN for Gilbert Syndrome), AST and ALT ≤ 3 times the ULN, serum creatinine concentration ≤ 1.5 mg/dl, non-hematological toxicity related to treatment drugs $\leq$ grade 2, and the absence of fever that would indicate an ongoing infection. If the patient did not meet these criteria, the administration of gemcitabine and nab-paclitaxel scheduled on day 8 was skipped and S-1 on day 8 and thereafter was withheld. One week later, the next course of chemotherapy was initiated.

The following indication of toxicities led to dose reduction by one step (gemcitabine to 600 mg/m^2 , nab-paclitaxel to 80 mg/m^2): neutropenia (grade 4), thrombocytopenia (grade 3), and febrile neutropenia. For grade 3 or higher non-hematological toxicity related to each drug, the dose of the relevant drug was reduced by one step. Stepwise reduction of gemcitabine ($700 \rightarrow 600 \rightarrow 500 \text{ mg/m}^2$) and nab-paclitaxel ($90 \rightarrow 80 \rightarrow 70 \rightarrow 60 \text{ mg/m}^2$) was allowed. For S-1,

the dose was reduced to 50/70/80 mg/day. If further dose reduction was necessary, study treatment was discontinued. The protocol treatment was discontinued when any of the following occurred: disease progression, grade 4 non-hematological adverse events, or delay in schedule of 4 weeks or more due to an adverse event. The dose level was set in 8 stages from -3 to 3 (Table 1). Up to six patients at each level were enrolled, and the dose level was increased or decreased according to the frequency of dose-limiting toxicity (DLT).

2.4 Definition of DLTs, MTD and RD

Dose-limiting toxicities (DLTs) were determined during the first course. With regard to S-1, administration of 75% or more of the S-1 doses was required for DLT evaluation. If >25% the planned dose of S-1 was not taken due to a toxicity, it was deemed a DLT. The DLTs were defined as drug-related adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 as one or more of the following events: $\geq$ grade 3 neutropenia with fever above 38.3°C, grade 4 neutropenia lasting 7 days or more, grade 4 thrombocytopenia, $\geq$ grade 3 non-hematologic toxicities, delay in course of more than 14 days due to an adverse event, or need to withhold study treatment on day 8 due to an adverse event.

1 The standard 3 + 3 method for dose finding was used. If DLT was not observed in
2 three patients, the dose was escalated to the next level. If DLT was observed in one or two of
3 three patients, three additional patients were enrolled at that level. Thus, if DLT was observed in
4 only one or two of six patients, the dose level was escalated. If all three initial patients (or if
5 three or more of six patients) experienced DLT, the dose level was de-escalated.

6 The MTD was defined as the highest dose level that produced the frequency of DLT
7 $\leq 33\%$. The RD was determined by taking into consideration the toxicity and tolerability
8 observed across the entire study.

9

10 **2.5 Pretreatment and follow-up evaluation**

11 Pretreatment evaluation included each patient's medical history and physical examination,
12 imaging tests using contrast-enhanced computed tomography or magnetic resonance imaging,
13 blood tests, electrocardiogram, and chest X-rays. Creatinine clearance was calculated using the
14 Cockcroft-Gault formula.

15 During the DLT evaluation period, 21 days of the first course, physical examination
16 and blood tests were performed on days 1, 8, and 15. After the DLT evaluation period (from the

second course), the tests were scheduled on day 1 and day 8. Tumor markers (CEA and CA19-9) were measured at the time patients were enrolled in the study and every month thereafter. Toxicity was evaluated using the CTCAE v4.0 throughout the study. Imaging tests were planned for every 2 months after the start of treatment and objective response rate (ORR) was assessed according to the RECIST version 1.1. Additional imaging tests were performed if clinically indicated or at the discretion of the treating physician.

3. Results

3.1 Patients characteristics

From March 2018 to October 2019, 20 patients were enrolled from two facilities (Table 2). According to National Comprehensive Cancer Network (NCCN) Guidelines 2017 Version 3, 19 patients had primary unresectable pancreatic cancer and one patient had locally recurrent disease after curative operation. No one received neoadjuvant or adjuvant chemotherapy.

3.2 DLTs

One patient developed DLT among three patients assigned to level 0, and three additional patients were treated at this level. Among these six patients, one experienced grade 3 skin rash on day 8 and two experienced grade 3 or 4 neutropenia on day 8, which lead to withholding the study treatment, and the dose was decreased to level -1 (gemcitabine 600 mg/m², nab-paclitaxel 90 mg/m², S-1 60/80/100 mg/day [$<1.25 \text{ m}^2/1.25\text{-}1.50 \text{ m}^2/>1.5 \text{ m}^2$]). At the reduced dose level, DLTs were observed in two of the first three patients, all of which were grade 3 neutropenia on day 8; three additional patients were treated at this level without DLTs. To confirm the safety of this treatment, eight additional patients were treated as an expansion cohort at dose level -1. However, two patients with biliary stent were not assessable for DLTs because of early treatment withdrawal due to cholangitis without neutropenia. DLT was not observed in the other six patients (Table 3). Eventually, at dose level -1, DLTs were observed in two of twelve (17%) assessable patients, and this dose was determined as the MTD.

3.3 Toxicity and RD

The median treatment period of the 20 patients was 21.9 weeks (range, 2.7-26.0). The most frequently observed toxicity during 8 courses of treatment was neutropenia (Table 4). Grade 3

1 febrile neutropenia was observed in 33% at dose level 0 during the second course of treatment.

2 No febrile neutropenia was observed at the reduced dose.

3 Non-hematological adverse events were mild. At dose level 0, grade 3 anorexia, skin

4 rash, and peripheral neuropathy were found in 17% of patients. At dose level -1, one grade 3

5 cholangitis that was not related to the study treatment developed after the first course. Neither

6 peripheral neuropathy nor other grade 3 or 4 non-hematological adverse events were observed.

7 Four of 14 patients developed grade 1 peripheral neuropathy when treated at dose level -1.

8 Gastrointestinal toxicities including nausea/vomiting, anorexia, and diarrhea were also mild at

9 dose level -1. There were no treatment-related deaths.

10 Considering the frequency of DLTs and adverse events throughout 8 courses, we

11 recommend dose level -1 for further studies.

12

13 **3.4 Efficacy**

14 Nineteen of 20 patients were evaluable for response. Eleven (58%) showed confirmed partial

15 response (PR), one achieved PR without confirmation, seven had stable disease (SD), and none

16 of them had progressive disease at the first evaluation. Median time to response was 2.0 months

(Table 5). At a median follow-up period of 16.4 months (range, 6.0-29.5), the median progression-free survival was 7.6 months (95 % CI, 4.3-10.5) (Fig.1), and the median overall survival was not reached yet.

4. Discussion

This study investigated the MTD and the RD of the gemcitabine/nab-paclitaxel/S-1 triplet combination chemotherapy in patients with unresectable pancreatic cancer. We determined that the MTD was dose level –1 (gemcitabine 600 mg/m², nab-paclitaxel 90 mg/m² on days 1 and 8, and S-1 50/70/80 mg/day [$<1.25\text{m}^2/1.25\text{-}1.50\text{m}^2/>1.5\text{m}^2$] on days 1–14) with a DLT frequency of 17%. At this dose, grade 3 or higher adverse events were hardly observed during the entire treatment course, and preliminary evaluation of antitumor activity revealed a relatively high (58%) confirmed response rate. Based on these results, we recommend this dose level for further investigation.

Our regimen using dose level –1 is well tolerated. Nab-paclitaxel (one of the key drugs

used to treat advanced pancreatic cancer) causes cumulative peripheral neuropathy, which can reduce quality of life or lead to the cessation of treatment. The MPACT phase 3 clinical trial showed that grade 3 or higher peripheral neuropathy was found at a frequency of 17% [4]. In the

current trial, grade 3 or higher peripheral neuropathy was found in only one patient treated at dose level 0, and no patients developed grade 2 or higher peripheral neuropathy at the recommended dose level -1. Other Grade 3 or higher non-hematological adverse events such as fatigue, vomiting, and diarrhea were documented in $\leq 5\%$ of cases following this triplet chemotherapy. In contrast, they were observed in $\geq 10\%$ of cases after gemcitabine plus nab-paclitaxel combination therapy or FOLFIRINOX therapy, which are standard treatments for unresectable pancreatic cancer [4, 5]. In gemcitabine plus nab-paclitaxel combination therapy, 1000 mg/m² of gemcitabine and 125 mg/m² of nab-paclitaxel are administered on days 1, 8, and 15 every 4 weeks, and the dose intensity is 750 mg/m²/week for gemcitabine and 94 mg/m²/week for nab-paclitaxel. On the other hand, at dose level -1 in our GeNeSIS trial, gemcitabine 600 mg/m² and nab-paclitaxel 90 mg/m² were administered on days 1 and 8, in combination with S-1 50/70/80 mg/day ($<1.25\text{m}^2/1.25\text{-}1.50\text{m}^2/>1.5\text{m}^2$) orally twice daily for 2 weeks, repeated every 3 weeks. The dose intensities of gemcitabine, nab-paclitaxel, and S-1 were 400 mg/m²/week, 60 mg/m²/week, and 233/327/373 mg/week, respectively. Lower doses of gemcitabine and nab-paclitaxel resulted in a lower incidence of grade 3 or higher non-hematological adverse events such as peripheral neuropathy.

With regard to hematological adverse events, grade 3 or higher hematological toxicities

had occurred about 80% at dose level -1. However, no grade 4 toxicities were observed at this

dose level, and grade 3 neutropenia was documented due to mandatory blood tests on day 15 in the first course. Grade 3 neutropenia on day 8 led to dose holding and was deemed a DLT according to the protocol. While this prevented dose escalation, withholding the treatment on day 8 resulted in no febrile neutropenia and chemotherapy could be continued without interruption at dose level –1.

In a previous phase 1 study of gemcitabine/nab-paclitaxel/S-1 combination as neoadjuvant chemotherapy for patients with locally advanced pancreatic cancer (the GAS trial), gemcitabine and nab-paclitaxel were administered on day 1, and S-1 was given on days 1–7; this was repeated every 2 weeks [13]. Although the frequency of DLT was relatively low, a response rate of 31% did not justify this neoadjuvant triplet chemotherapy regimen [13]. Hypothesizing that further dose escalation or modification of the administration schedule might be necessary to show antitumor activity, we performed the current GeNeS1S trial. The dose intensities in our study were slightly lower than those of the GAS trial for gemcitabine (400 vs 500 mg/m²/week) and nab-paclitaxel (60 vs 63 mg/m²/week). Despite this, we observed a higher response rate (58% compared to 31% in GAS). We infer that the improved efficacy in our study might be due to the slightly higher dose intensity of S-1 in this study (233/327/373 mg/week) than that in the GAS study (210/280/350 mg/week) as well as the longer exposure period to S-1 (2 weeks) compared to GAS study (one week). The S-1 dose and administration schedule might play a more important

1 role among the three drugs in terms of antitumor effect, as suggested by a previous study [14].

2 Despite it being a triplet chemotherapeutic approach, the advantage of our current
3 regimen is that it is well tolerated at dose level –1 and appears to exert a high antitumor activity.

4 However, we enrolled a small number of Japanese patients, and further clinical trials are required
5 in order to confirm the efficacy and tolerability.

6 In conclusion, chemotherapy regimen of gemcitabine 600 mg/m² and nab-paclitaxel 90
7 mg/m² on days 1 and 8 combined with oral S-1 50/70/80 mg/day (<1.25 m²/1.25-1.50 m²/>1.5
8 m²) on days 1–14, repeated every 3 weeks is well tolerated and recommended for patients with
9 unresectable pancreatic cancer. This triplet regimen appears efficacious and has fewer side effects,
10 although further clinical studies to validate our observations are warranted. In this regard, we are
11 now conducting a phase 2 study of this combination treatment for unresectable pancreatic cancer.

1

2 **5. Declarations**

3 **Funding**

4 No funding was received for conducting this study.

5

6 **Conflict of interest**

7 Masanori Toyoda has received a honoraria from Taiho Pharmaceutical Co., Ltd. Hironaga

8 Satake has received a research grant from Taiho Pharmaceutical Co., Ltd, a honoraria from Eli

9 Lilly Japan Co., Ltd. and Taiho Pharmaceutical Co., Ltd. Hisateru Yasui has received a

10 honoraria from Eli Lilly Japan Co., Ltd. and Taiho Pharmaceutical Co., Ltd. Hironobu Minami

11 has received a research grant and personal fees from Eli Lilly Japan Co., Ltd. and Taiho

12 Pharmaceutical Co., Ltd. The remaining authors have no conflict of interest to declare.

13

14 **Ethics approval**

1 This study was conducted in compliance with the ethical principles of the Declaration of
2 Helsinki, the principles of Good Clinical Practice and all applicable regulations. The study
3 protocol was approved by the institutional review board of each participating institution, and
4 written informed consent was obtained from all participants.

5

6 **Consent to participate**

7 Informed consent was obtained from all individual participants included in the study.

8

9 **Consent for publication**

10 Patients signed informed consent regarding publishing their data.

11

12 **Availability of data and material**

13 The content of this manuscript has not been published or submitted for publication elsewhere
14 and is not under consideration elsewhere.

1

2 **Authors' contributions**

3 All authors have contributed significantly, and that all authors are in agreement with the content
4 of the manuscript.

5

6 **6. References**

- 7 1. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617
- 8 2. Matsuno S, Egawa S, Fukuyama S et al (2004) Pancreatic Cancer Registry in Japan: 20
9 years of experience. Pancreas 28:219–230
- 10 3. Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22:9694–
11 9705
- 12 4. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased Survival in Pancreatic Cancer with
13 nab-Paclitaxel plus Gemcitabine. N Engl J Med 369:1691-1703
- 14 5. Thierry C, Francoise D, Marc Y et al (2011) FOLFIRINOX versus Gemcitabine for
15 Metastatic Pancreatic Cancer. N Engl J Med 364:1817-1825

6. Ueno H, Ioka T, Ikeda M et al (2013) Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. *J Clin Oncol* 31:1640-1648
7. Okusaka T, Ikeda M, Fukutomi A et al (2014) Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. *Cancer Sci* 105:1321-1326
8. Sasaki Y, Hamada K, Kaneta T et al (2015) Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? *Cancer Sci* 106:1100
9. Ueno H, Ikeda M, Ueno M et al (2016) Phase I/II study of nab- paclitaxel plus gemcitabine for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 77:595–603
10. Yan S, Sui Z, Quanli H et al (2017) Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. *Oncotarget* 8:92401-92410
11. Wen Z, Chunxia D, Yongkun S et al (2018) Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. *Cancer Chemother Pharmacol* 82:655-660

12. Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. *Ann Oncol* 30:1950-1958
13. Kondo N, Murakami Y, Uemura K et al (2017) A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. *Cancer Chemother Pharmacol* 79:775-781
14. Tanaka H, Kanda M, Morita S et al (2017) Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003). *Int J Clin Oncol* 22:1052-1059

Figure Caption

Fig.1 Kaplan-Meier Curve for progression-free survival

The median progression-free survival was 7.6 months (95 % confidence interval, 4.3-10.5)

Table 1. Dose level

Dose level	Gemcitabine (mg/m ²)	Nab-paclitaxel (mg/m ²)	S-1 (mg/day)
3	800	100	80/100/120
2	800	100	60/80/100
1	700	100	60/80/100
0	700	90	60/80/100
−1	600	90	50/70/80
−2a	500	90	50/70/80
−2b	600	80	50/70/80
−3	500	80	50/70/80

Table 2. Patient characteristics (n=20) (%)

Age (years)	
Median	61
Range	42–76
Gender	
Female	6 (30)
Male	14 (70)
ECOG-PS	
0	14 (70)
1	6 (30)
Tumor location	
Head	6 (30)
Body	10 (50)
Tail	4 (20)
Maximum tumor size (mm)	
Median	41
Range	18–80
Clinical presentation	
Locally advanced	6 (30)
Locally recurrent	1 (5)
Metastatic	13 (65)
Biliary drainage	
Yes	5 (25)
No	15(75)
CA19-9 level (U/mL)	
Median	120
Range	<1–17251

ECOG-PS: Eastern Cooperative Oncology Group performance status

Table 3. Summary of DLTs

Dose level	No. of patients	No. of DLT (%)	Details of DLT
0	6	3 (50%)	• Grade 3 Skin rash • Grade 3 Neutropenia on day 8 • Grade 4 Neutropenia on day 8
-1	12	2 (17%)	• Grade 3 Neutropenia on day 8 • Grade 3 Neutropenia on day 8

Table 4. Adverse events

	Level 0			Level –1			All patients		
	(n=6)			(n=14)			(n=20)		
	Grade			Grade			Grade		
	1/2	3/4	All	1/2	3/4	All	1/2	3/4	All
	no. (%)			no. (%)			no. (%)		
Hematological									
adverse event									
Leukopenia	3 (50)	3 (50)	6 (100)	11(79)	2 (14)	13 (93)	14 (70)	5 (25)	19 (95)
Neutropenia	0 (0)	6 (100)	6 (100)	4 (29)	9 (64)	13 (93)	4 (20)	15 (75)	19 (95)
Febrile neutropenia	–	2 (33)	2 (33)	–	0 (0)	0 (0)	–	2 (10)	2 (10)
Anemia	6 (100)	0 (0)	6 (100)	14 (100)	0 (0)	14 (100)	20 (100)	0 (0)	20 (100)
Thrombocytopenia	5 (83)	0 (0)	5 (83)	11 (79)	1 (7)	12 (86)	16 (80)	1 (5)	17 (85)
Non-hematological									
adverse event									
Fatigue	4 (67)	0 (0)	4 (67)	10 (71)	0 (0)	10 (71)	14 (70)	0 (0)	14 (70)
Nausea / Vomiting	2 (33)	0 (0)	2 (33)	7 (50)	0 (0)	7 (50)	9 (45)	0 (0)	9 (45)
Anorexia	3 (50)	1(17)	4 (67)	6 (43)	0 (0)	6 (43)	9 (45)	1 (5)	10 (50)
Diarrhea	1 (17)	0 (0)	1 (17)	4 (29)	0 (0)	4 (29)	5 (25)	0 (0)	5 (25)
Skin rash	4 (67)	1 (17)	5 (83)	5 (36)	0 (0)	5 (36)	9 (45)	1 (5)	10 (50)

Peripheral neuropathy	2 (33)	1 (17)	3 (50)	4 (29)	0 (0)	4 (29)	6 (30)	1 (5)	7 (35)
Oral mucositis	1 (17)	0 (0)	1 (17)	4 (29)	0 (0)	4 (29)	5 (25)	0 (0)	5 (25)
Cholangitis	1 (17)	0 (0)	1 (17)	2 (14)	1 (7)	3 (21)	3 (15)	1 (5)	4 (20)
AST/ALT elevation	3 (50)	0 (0)	3 (50)	10 (71)	0 (0)	10 (71)	13 (65)	0 (0)	13 (65)

AST/ALT: aspartate aminotransferase/alanine aminotransferase

Table 5. Efficacy

	Level 0 (n=6)	Level -1 (n=13)	All (n=19)
Response –no.			
Complete response	0	0	0
Partial response	4	7	11
Stable disease	2	5	7
Progression disease	0	0	0
Objective response rate (%)	67	54	58
Time to response (months)			
Median	2.0	1.9	2.0
Range	1.9 – 4.3	1.8 – 5.6	1.8 – 5.6




Fig.1